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Approximately half of genetic disease-associated mutations cause aberrant splicing. How-
ever, a widely applicable therapeutic strategy to splicing diseases is yet to be developed.
Here, we analyze the mechanism whereby IKBKAP-familial dysautonomia (FD) exon 20
inclusion is specifically promoted by a small molecule splice modulator, RECTAS, even
though IKBKAP-FD exon 20 has a suboptimal 5′ splice site due to the IVS20+ 6 T > C
mutation. Knockdown experiments reveal that exon 20 inclusion is suppressed in the absence
of serine/arginine-rich splicing factor 6 (SRSF6) binding to an intronic splicing enhancer in
intron 20. We show that RECTAS directly interacts with CDC-like kinases (CLKs) and
enhances SRSF6 phosphorylation. Consistently, exon 20 splicing is bidirectionally manipu-
lated by targeting cellular CLK activity with RECTAS versus CLK inhibitors. The therapeutic
potential of RECTAS is validated in multiple FD disease models. Our study indicates that
small synthetic molecules affecting phosphorylation state of SRSFs is available as a new
therapeutic modality for mechanism-oriented precision medicine of splicing diseases.
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Splicing mutations through the creation or disruption ofsplicing cis-elements induce constitutive gain or loss or thealternative splicing of target exons, which in turn prevent
functional protein production by generating stop codons or fra-
meshifts. Pre-mRNA splicing is catalyzed by five essential small
nuclear RNAs (U1, U2, U4, U5, and U6 snRNA) and more than
100 proteins. In addition to these essential factors (e.g., U1 small
nuclear ribonucleoprotein (snRNP) to recognize the 5′-splice site
and U2 snRNP to recognize the branchpoint sequence), various
trans-acting splicing factors are recruited to cis-regulatory ele-
ments to orchestrate alternative splicing. Several approaches have
been taken to amend mutation-derived splicing defects by tar-
geting either cis-regulatory elements or trans-acting splice factors.
The former approach includes the antisense-oligonucleotide drug
nusinersen, which rescues deficient SMN2 exon 7 inclusion for
spinal muscular atrophy therapy1–3, and small-molecule com-
pounds, such as SMN-C3 and RG7916, that also promote SMN2
exon 7 inclusion, in part by directly binding to an imperfect RNA
helix formed by the exon 7 5′-splice site and U1 snRNA acting for
bulge repair4–8. Examples of the latter approach include small-
molecule inhibitors for CDC-like kinase (CLK) or serine/argi-
nine-rich protein kinase (SRPK)9, which then inactivate serine/
arginine-rich splicing factors (SRSFs) through serine phosphor-
ylation in their carboxy-terminal RS domain. Previously, we
synthesized CLK inhibitors10 and demonstrated their therapeutic
potential in disease models of cystic fibrosis (c.3849+ 10 kb C > T
mutation of cystic fibrosis transmembrane conductance
regulator (CFTR))11, Duchenne muscular dystrophy (c.4303 G >
T mutation of dystrophin)12, and anhidrotic ectodermal dysplasia
with immunodeficiency (EDA-ID; IVS6+ 866 C > T mutation of
NF-kappa-B essential modulator (NEMO))13.
In parallel, we developed a dual-color splicing reporter system
combining two different fluorescent proteins to identify both cis-
elements and trans-acting factors involved in targeting alternative
splicing events in worms, mice, and cultured cells14–16. Recently,
we applied this system to screen a chemical library and found a
small-molecule RECTAS, which corrects abnormal splicing
caused by the IVS20+ 6 T > C splicing mutation of the (inhibitor
of κ light polypeptide gene enhancer in B-cells, kinase complex-
associated protein (IKBKAP) gene17. The homozygous mutation
is mainly found in the Ashkenazi Jewish population and is
responsible for >99.5% of cases of familial dysautonomia (FD)
(also known as Riley-Day syndrome or hereditary sensory/auto-
nomic neuropathy type III)18–20. FD is an autosomal recessive
genetic disease, and autonomic neurons and peripheral sensory
neurons derived from neural crest cells are impaired in devel-
opment, function, and survival18–20. Patients with FD exhibit
various symptoms including cardiovascular instability, recurrent
pneumonia, vomiting/dysautonomic crisis, gastrointestinal dys-
function, decreased sensitivity to pain and temperature, and
defective lacrimation. The IVS20+ 6 T > C mutation causes
abnormal IKBKAP exon 20 skipping, due to impaired recognition
of the mutant 5′ splice site by U1 snRNP21,22, leading to a fra-
meshift and the generation of a premature termination codon in
exon 21 of IKBKAP mRNA20. This frameshift in turn results in
reduced expression of IKAP (or ELP1), compromising tRNA
modification and neuronal cell survival17,23,24. RECTAS directly
affects mRNA splicing, and our transcriptome analyses revealed
that RECTAS affects the splicing of only a limited set of genes,
suggesting that it has high specificity and a direct role in cor-
recting IKBKAP aberrant splicing17. Sequence analysis of the
responsive exons suggests that RECTAS promotes exon recog-
nition by either inhibiting splicing repressors, such as hetero-
geneous nuclear ribonucleoproteins (hnRNPs), or stimulating
splicing activators. RBM24 functions as a tissue-dependent splice
activator by binding to a cryptic intronic splicing enhancer
element (IVS20+ 13 to +29) downstream of the intronic 5′
splice-site mutation of IKBKAP-FD and promotes U1 snRNP
recognition of the mutant 5′ splice site25. Thus, undetectable
RBM24 expression in neuronal tissues explains the greater extent
of aberrant splicing of IKBKAP-FD exon 20 in neurons25. In this
study, we revealed that SRSF6 is also involved in exon 20
recognition and that RECTAS specifically rectifies aberrant spli-
cing by promoting the SRSF6 function.
Results
Binding of SRSF6 to an intronic splice enhancer (ISE) is
required for IKBKAP-FD exon 20 inclusion. IKBKAP-FD exon
20 has a suboptimal 5′ splice site, due to the IVS20+ 6 T > C
mutation. It lacks complementarity to U1 snRNA at the −1 and
+6 positions (Fig. 1a), and such suboptimal splice sites are more
prone to be regulated by alternative splicing factors11–13,26,27, as
we reported for promotion of spliceosomal recognition of this 5′
splice site by RBM24 in skeletal muscle tissue25. The RNA
sequencing (RNA-Seq) evaluation of the transcriptome of FD
patient fibroblasts homozygous for the IKBKAP IVS20+ 6 T > C
mutation following RECTAS treatment revealed a highly selective
action of RECTAS on IKBKAP-FD exon 20, with the second-
highest ΔPSI (percent spliced-in) of 618 altered splicing events
with ≥0.1 of | ΔPSI | (Fig. 1b, c and Supplementary Data 1). As we
supposed that RECTAS rescued exon 20 skipping as part of the
overall context of splicing regulation, we checked whether RBM24
function is involved in RECTAS-induced exon 20 inclusion.
Western blot for human tissues as well as HeLa and FD patient
fibroblasts, responder cells to RECTAS17, indicates RBM24
expression is exclusive in heart and skeletal muscle but absent in
RECTAS responder cells, irrespective of RECTAS treatment
(Fig. 1d). These observations ruled out the involvement of
RBM24 in RECTAS-induced splice modification. Therefore, we
hypothesized that RECTAS interacts with an unidentified splicing
regulator(s) that promotes the restoration of normal exon 20
inclusion. To test this hypothesis, we examined loss-of-function
study by RNAi knockdown for individual SRSFs, a major family
of alternative splicing activators, and compared the extent of
RECTAS-induced promotion of IKBKAP-FD exon 20 inclusion,
using a dual fluorescent splicing reporter system we previously
developed (Fig. 1e)11,13,17. We observed a marked reduction
(~60%) in exon 20 inclusion when SRSF6 was knocked down
(Fig. 1f, g), whereas depletion of nine other SRSFs yielded no or
only a modest effect on this splicing event (Fig. 1f, g).
These observations indicate that SRSF6 is a crucial regulator of
IKBKAP-FD exon 20 inclusion in the therapeutic splicing
environment provided by RECTAS treatment. We further asked
whether SRSF6 directly controls IKBKAP-FD exon 20 inclusion.
For this purpose, we searched for potential SRSF6-recognition
sites based on the systematic evolution of ligands by exponential
enrichment (SELEX) motifs for SRSF6 with ESE finder 3.028,29 for
a region downstream or upstream of the exon 20 5′-splice site
(−100 to +100 nucleotides (nt)) of IKBKAP. We identified three
candidate motifs 21, 45, and 58 nt downstream of the exon 20 5′
splice site (site-a, site-b, and site-c, respectively, in Fig. 1h).
Subsequent validation of SRSF6 binding by RNA pull-down assay
with biotin-conjugated RNAs revealed that only site-b has a high
affinity to a cellular protein inferred to be SRSF6 (Fig. 1i). The
band of expected SRSF6 disappeared in the pull-down products
from SRSF6-knockdown cells, confirming its identity as SRSF6
(Fig. 1j). In addition, SRSF6 binding was lost when point
mutations (site-b(mt) in Fig. 1h) were introduced in the SRSF6-
binding motif (Fig. 1k). The functional significance of SRSF6
binding for IKBKAP-FD exon 20 recognition was subsequently
examined by introducing a site-b(mt) mutation into the IKBKAP-
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Fig. 1 IKBKAP-FD exon 20 requires SRSF6 binding to an ISE. a The IKBKAP exon 20 5′ splice site has nearly optimal pairing to U1 snRNA, whereas the
IVS20+ 6 T > C creates an additional mismatch at +6 position, resulting in suboptimal recognition by U1 snRNP. Blue dots indicate base pairing. b Top 100
differential splice events by |ΔPSI (PSIRECTAS-PSIDMSO) | following RECTAS treatment (2 µM, 8 h) in FD patient fibroblasts. c Sashimi plot with junction read
number of IKBKAP-FD exon 19–22 for DMSO- or RECTAS-treated FD patient fibroblasts. The displayed read count range was set to 0–50. d RT-PCR for
RBM24 expression in human tissues, and cell lines treated with 10 µM RECTAS or 0.1% DMSO for 24 h. RBM24 and ACTB were detected with primers
oAM669+ oAM671 and oAM13+ oAM14, respectively. e Diagram of reporter system for IKBKAP-FD exon 20 splicing13,17. GFP is translated when exon
20 is included (E20(+)), whereas RFP is translated when it is skipped (E20(−)). f, g Microscopic images (f) and quantification of IKBKAP-FD exon 20
inclusion (g), following treatment with RECTAS (10 µM) or 0.1% DMSO for 24 h in HeLa cells transfected with the indicated siRNAs for 72 h. h SRSF6-
binding motifs starting at +21 nt (site-a), +45 nt (site-b), and +58 nt (site-c), predicted by ESE finder 3.028,29 are shown. RNA sequences for pull-down
assays are indicated. Asterisks in site-b(mt) indicate mutated ribonucleotides. ISE-20 from Sinha et al.30 is also indicated. i–k Western blot of SRSF6 by
1H4 antibody for RNA pull-down products or no bait RNA control for HeLa cells (i), site-b pull-down products for HeLa cells treated with siRNA for 72 h (j),
and site-b and site-b(mt) RNA pull-down products for HeLa cells (k). l Quantification of IKBKAP exon 20 inclusion rate, following RECTAS treatment for 24
h in HeLa cells with IKBKAP-FD or site-b(mt)-mutant IKBKAP (FD site-b(mt)) reporter. Data from four replicates are shown in (f), (g), and (l), and two
replicates are shown in (i), (j), and (k). Representative data of two experiments are shown in (d). Columns, mean; bars, SE; n.s., P≥ 0.05; **P < 0.01; ***P <
0.001 for unpaired two-tailed t test in (g) (vs. the RECTAS 10 µM of si-NS: si-SRSF1, P= 2.3 × 10−3; si-SRSF2, P= 1.7 × 10−4; si-SRSF4, P= 0.94; si-SRSF6,
1.5 × 10−7; si-SRSF7, P= 1.9 × 10−4; si-SRSF8, P= 1.0 × 10−4; si-SRSF9, 3.0 × 10−3; si-SRSF10, P= 0.28; si-SRSF11, P= 6.1 × 10−4; si-SRSF12, P= 1.8 × 10−4)
and (l) (vs. the FD of corresponding RECTAS concentration: 0 µM, P= 2.0 × 10−4; 5 µM, P= 4.4 × 10−5; 10 µM, P= 1.0 × 10−4).
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FD exon 20 splicing reporter, and a reduction in RECTAS-led
exon 20 inclusion was observed, comparable to that seen in
SRSF6 knockdown cells (~60%) (Fig. 1l). These combined
observations indicate that site-b is an ISE, and whose recognition
by SRSF6 is crucial to provide a splicing context that restores
normal splicing of IKBKAP-FD exon 20 in the presence of
RECTAS. We note that the identified SRSF6-dependent ISE
overlaps with a 20-nt region with ISE activity (dubbed ISE-20)
revealed by our previous antisense-oligonucleotide walk30
(Fig. 1h). In addition, the SRSF6-binding site (+45 to +50)
somewhat close to that of RBM24 (+13 to +29)25 imply RBM24
binding may interfere with SRSF6 binding, and may impair the
effect of RECTAS in tissues with RBM24 expression.
Reciprocal control of IKBKAP-FD exon 20 splicing by REC-
TAS and CDC-like kinase (CLK) inhibitors suggests that CLKs
are pivotal regulators. As SRSF6 is functionally activated by
serine phosphorylation in its carboxyl-terminal RS domain, we
next asked if kinases upstream of SRSF6 promote IKBKAP-FD
exon 20 inclusion. For this purpose, we examined the effects of
the following synthetic inhibitors of potential upstream SRSF
kinases on IKBKAP-FD exon 20 recognition with our splicing
reporter: TG003 for CLKs;10,12,13 INDY, CaNDY, and ALGER-
NON for dual-specificity tyrosine phosphorylation-regulated
kinases (DYRKs)31–33 and CLKs11, and SRPIN340 for SRSF
protein kinases (SRPKs)34,35. We used RECTAS and the plant
cytokinin kinetin17,36,37 as controls with opposite effect to that
expected for inhibitors of SRSF6 kinases. Treatment of cells with
TG003, INDY, CaNDY, and ALGERNON at 2 and 10 µM
resulted in the dose-dependent promotion of IKBKAP-FD exon
20 skipping (Fig. 2a, b), in contrast to the increased inclusion of
exon 20 by RECTAS treatment (Fig. 2a, b), whereas the exon-
inclusion effect of kinetin was considerably weaker, consistent
with our prior observation17 (Fig. 2a, b). SRPIN340 had no effect
on IKBKAP-FD exon 20 splicing (Fig. 2a, b). Some inhibitors of
CLKs and DYRKs show cross-inhibition due to structural simi-
larity at the ATP-binding pocket between these two kinase
families11,25,31–33,38,39, and depletion of CLK or DYRK isoforms
by RNAi was conducted to distinguish their effects. As a result,
we found that the depletion of CLK isoforms inhibited IKBKAP-
FD exon 20 recognition similarly to SRSF6-depleted cells
(Fig. 2c), whereas depletion of DYRK isoforms had no effect
(Fig. 2c). Moreover, overexpression of CLK1 mimicked the effect
of RECTAS on the inclusion of IKBKAP-FD exon 20 (Fig. 2d),
whereas the kinase-inactive K191M mutant of CLK1 had no effect
(Fig. 2d). Dependency of RECTAS activity on CLK activities was
further assessed by evaluating RECTAS response in cells under
CLK inhibition. We recently reported CaNDY as a potent pan-
CLK inhibitor11, and found that there is no exon 20 inclusion-
promoting activity by RECTAS when CLKs were functionally
inactivated (Fig. 2e). Moreover, we found SRSF6 overexpression
also has exon 20 inclusion-promoting activity as seen in RECTAS
treatment or CLK1 overexpression (DMSO conditions in Fig. 2f).
However, this SRSF6 overexpression effect was also canceled
when CLKs are inhibited (CaNDY conditions in Fig. 2f). These
observations together support the idea that RECTAS depends on
CLK1 activity for exon 20 inclusion-promoting activity. We
further validated the effects of compound treatment (RECTAS,
TG003, INDY, CaNDY, ALGERNON, and SRPIN340) and
knockdown of SRSF6 or CLK in FD patient fibroblasts with the
homozygous IKBKAP-FD IVS20+ 6 T > C mutation, and con-
firmed the increased IKBKAP-FD exon 20 skipping by CLK
inhibition (Fig. 2g and Supplementary Fig. 1a) or depletion for
SRSF6 or CLK (Fig. 2h and Supplementary Fig. 2a) for the
endogenous transcripts. Primary fibroblasts without IVS20+ 6 T
> C mutation of IKBKAP showed no exon 20 skipping following
CLK inhibition (Fig. 2i and Supplementary Fig 1b) or depletion
for SRSF6 or CLK (Fig. 2j and Supplementary Fig. 2b), showing
the effect of RECTAS depends on the suboptimal nature of exon
20 donor sites due to IVS20+ 6 T > C (Fig. 1a). In addition, we
also compared RECTAS with compounds previously reported for
exon 20 inclusion promotion40, and we confirmed that RECTAS
shows the highest activity (0.72 μM of EC25) over those we tested
(Fig. 2k, l). Two compounds, kinetin and (−)-epigallocatechin
gallate (EGCG), reached EC25 of RECTAS (Fig. 2k, m, n), but
were 15.5- and 241-fold less potent and there was also cytotoxi-
city around the effective range for EGCG (Fig. 2n).
Having confirmed that CLK-dependent SRSF6 activation is
required for restoration of normal splicing of IKBKAP-FD exon
20 by RECTAS, we then asked whether RECTAS affects the
functions of CLKs and SRSF6. For this purpose, we synthesized a
biotin-linked RECTAS analog (b-RECTAS) (Fig. 3a), which
retained the IKBKAP-FD exon 20 inclusion-promoting activity,
whereas biotin alone at 50 μM had no effect (Fig. 3b). We used b-
RECTAS in a compound pull-down assay from HeLa cell lysates
by neutravidin to evaluate its binding affinity to CLK1 and SRSF6.
We found that b-RECTAS binds to CLK1 in a dose-dependent
manner but not to SRSF6 (Fig. 3c). Recombinant CLK1 protein
also bound to b-RECTAS in a dose-dependent manner, indicating
their direct interaction (Fig. 3d). The interaction between b-
RECTAS and CLK1 was effectively competed out by incubating
with 500 nmol of free RECTAS (lane 6 in Fig. 3d). Western
blotting for RECTAS-treated FD patient fibroblasts revealed that
the SRSF6 phosphorylation was enhanced following RECTAS
treatment (Fig. 3e), and this effect was detected by 6 h and
disappeared by 10 h after washout of RECTAS (Fig. 3f). Since it
was recently reported that several small molecules stabilize U1
snRNA-donor paring for SMN exon 7 through 5′-splice-site bulge
repair8, we tested whether RECTAS has such activity on IKBKAP
exon 20 donor site. RNA pull-down assay by IKBKAP exon 20
donor sequences with or without IVS20+ 6 T > C reproduced
weakened affinity to U1 snRNP (detected by U1-70k and SmB/B′
subunits) by IVS20+ 6 T > C mutation (lanes 4 and 6 in Fig. 3g),
whereas RECTAS had no effect on their affinity, denying its role
in donor-U1 snRNA paring (lanes 5 and 7 in Fig. 3g).
The therapeutic effect of RECTAS in FD disease models.
Having established the mechanism and target selectivity of
RECTAS, we then assessed its therapeutic potential for FD, in two
FD disease models: iPSC-SNs and IKBKAP-FD transgenic mice.
As alternative splicing undergoes tissue-dependent regulation due
to a varied distribution of RNA-binding proteins41, it is desirable
to assess therapeutic potential in the context of sensory or
autonomic neurons, which are affected in FD patients18–20. For
efficient preparation of induced pluripotent stem cells-derived
sensory neurons (SNs), we employed the embryoid-body method
for the initial differentiation step (detailed in “Methods”). This
modification resulted in higher viability and rapid derivation of
the SNs (BRN3A+ /TUBB3+ ) on day 12 (Fig. 4a) (see “Meth-
ods” for details). The effect of the compounds was tested by
adding kinetin, RECTAS, or solvent only (0.1% dimethyl sulf-
oxide (DMSO)) to the culture media during the whole differ-
entiation process. We found that 10 µM of RECTAS completely
restored IKBKAP-FD exon 20 inclusion (lane 7 in Fig. 4b), while
10 µM of kinetin did not eliminate exon 20 skipping completely
in patient iPSC-SNs (lane 6 in Fig. 4b). The effect of RECTAS on
exon 20 inclusion was transient, and beginning around 2 h after
the incubation and lasting for ~4 h after washout (Supplementary
Fig. 3). We also examined the effect of CLK inhibition for
RECTAS responsivity in iPSC-SNs. Consistent with observations
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in IKBKAP-FD reporter-transfected HeLa cells, iPSC-SNs showed
impaired RECTAS activity by CLK inhibition with CaNDY
treatment (Fig. 4c).
Next, we attempted to test the therapeutic potency of RECTAS
in an FD mouse model. Prior to in vivo administration, we
examined whether RECTAS also has an exon 20 inclusion-
promotive effect in mice neural tissue culture, neuro 2A cells. We
confirmed a marked induction of exon 20 inclusion in neuro 2A
(Fig. 4d, e), indicating activity of RECTAS for human IKBKAP-
FD exon 20 is retained in murine cells. RT-PCR was also
confirmed for RECTAS-induced exon 20 inclusion for human
IKBKAP-FD, without alteration in endogenous mouse Ikbkap
exon 19 (Fig. 4f), which is homologous to exon 20 in human and
lacking IVS20+ 6 T > C mutation (Supplementary Fig. 4). Then
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Fig. 2 A pivotal control of IKBKAP-FD exon 20 splicing by RECTAS and a CLK inhibitor. a, b Microscopic images (a) and IKBKAP-FD exon 20 inclusion
rates (b) following compound treatment (2 or 10 µM) or solvent only (0.1% DMSO) for 24 h in HeLa cells transfected with IKBKAP-FD reporter. ALG
indicates ALGERNON in (b). c HeLa cells with IKBKAP-FD reporter were transfected with siRNA for si-SRSF6, si-CLKs, si-DYRKs, or si-NS for 72 h, and
IKBKAP-FD exon 20 inclusion rates were plotted by GFP/RFP ratio. d IKBKAP-FD exon 20 inclusion was quantified by the GFP/RFP ratio of IKBKAP-FD
reporter in HeLa cells, transfected with empty vector (control), CLK1 expression vector, or inactive mutant CLK1 (K191M) expression vector for 24 h, or
treated with RECTAS (2 µM) for 24 h. e, f IKBKAP-FD exon 20 inclusion rates in response to RECTAS treatment for 24 h (e) or transfection with SRSF6
expression vector for 24 h (f) were quantified by GFP/RFP ratio in HeLa cells, transfected with IKBKAP-FD reporter with or without CaNDY treatment (10
µM, 24 h). control, empty p3XFLAG-CMV14 vector transfection in (f). g, h RT-PCR for IKBKAP-FD exon 19–21 for FD patient fibroblasts (P2) treated with
compounds (2 or 10 µM) or solvent only (0.1 % DMSO) for 24 h (g), or transfected with si-NS, si-SRSF6, or si-CLKs for 72 h (h). i, j RT-PCR for IKBKAP-FD
exon 19–21 for fibroblasts from a healthy individual (C1) treated with compounds (2 or 10 µM) or solvent only (0.1% DMSO) for 24 h (i), or transfected
with si-NS, si-SRSF6, or si-CLKs for 72 h (j). k–n 25% effective concentration (EC25) and 50% cytotoxic concentration (CT50 for 72 h treatment) were
shown for indicated compounds. EC25 was determined with %GFP of 20 µM RECTAS set to 100%. Individual plots for RECTAS (l), kinetin (m), and
(−)-epigallocatechin gallate (EGCG) (n) are shown separately. Data from four replicates are shown in (a), (b), (c), (e), and (f), six replicates in (d), four
replicates for %GFP, and three replicates for %Cell viability in (k–n). Representative data from two replicates are shown in (g–j). Columns, mean; bars, SE;
n.s., P≥ 0.05; *P < 0.05; **P < 0.01; ***P < 0.001 for unpaired two-tailed t test in (b) (vs. the 0.1% DMSO control) (kinetin: 2 µM, P= 9.2 × 10−2; 10 µM, P
= 8.8 × 10−5; RECTAS: 2 µM, P= 3.2 × 10−8; 10 µM, 3.2 × 10−9; TG003: 2 µM, 2.3 × 10−5; 10 µM, 1.3 × 10−5; INDY: 2 µM, 1.5 × 10−6; 10 µM, 1.6 × 10−6;
ALG: 2 µM, P= 4.1 × 10−3; 10 µM, P= 7.1 × 10−3; SRPIN340: 2 µM, P= 0.90; 10 µM, P= 0.27), (c) (vs. si-NS: si-SRSF6, P= 6.7 × 10−5; si-CLKs, P= 7.1 ×
10−5; si-DYRKs, P= 0.11), (d) (vs. control vector: CLK1, P= 1.1 × 10−9; K191M, P= 1.0 × 10−5; RECTAS, P= 6.1 × 10−12), (e) (P= 9.0 × 10−3 and P= 3.9 ×
10−7 for RECTAS 2 µM and 10 µM without CaNDY, and P= 0.53 and 0.13 for RECTAS 2 µM and 10 µM with CaNDY), and (f) (DMSO, P= 3.1 × 10−5;
CaNDY, P= 8.0 × 10−2). E20 (+), exon 20 inclusion product; E20 (−), exon 20 skipping product in (a), (g), (h), (i), and (j); ND, not detectable in (i) and
(j); PSI, percent spliced-in in (g–j). IKBKAP and ACTB were detected with primers oAM138+ oAM139 and oAM13+ oAM14, respectively in (g–j).
Fig. 3 RECTAS directly interacts with CDC-like kinase 1 (CLK1), and it enhances cellular SRSF6 activity. a Structures of RECTAS and b-RECTAS. b Extent
of IKBKAP-FD exon 20 inclusion represented by GFP/RFP ratio, following treatment with biotin (50 µM), RECTAS (2 µM), b-RECTAS (2, 10, and 50 µM), or
solvent only (0.1% DMSO) for 24 h in reporter-transfected HeLa cells. c, d Western blotting of pull-down products by b-RECTAS (0, 100, or 200 nmol/
reaction) for HeLa cells transfected with a flag-tagged CLK1 expression vector (c) or GST-tagged recombinant CLK1 (d). RECTAS (500 nmol) was
incubated with 100 nmol b-RECTAS for the competition assay in (d). e, f Western blot (e) for phosphor SRSF6 in FD patient primary fibroblasts (P1 and
P2), treated with RECTAS (10 µM) or solvent only (0.1% DMSO) for 24 h. f Phosphor SRSF6 in FD fibroblasts (P1) was quantified at 0, 6, 10, 24 h after
RECTAS (10 µM) treatment (columns, 0 h, 6 h, 10 h, and 24 h), as well as 10 h after washout of compound following RECTAS treatment (10 µM) for 24 h
(column, wo). Lamin B1 served as a loading control in (e). g Western blot for U1-70k and SmB/B’ in pull-down products with biotin-conjugated RNA
surrounding IKBKAP exon 20 donor site with (oAM154) or without (oAM153) IVS20+ 6 T > C mutation (labeled as FD and WT, respectively). Pull-down
was conducted in the presence of 10 µM RECTAS with 1% DMSO, or 1% DMSO only. RNA (−), control sample without RNA bait. Input, HeLa nuclear
extract of 5% input amount. Representative data from four replicates were shown in (b). Representative data from two replicates were shown in (c), (d),
and (g). Data from two experiments are shown in (e, f) and three experiments are shown in (f). Columns, mean; bars, SE; n.d. ≥0.05; *P < 0.05; ***P <
0.001 for unpaired two-tailed t test in (b) (biotin, P= 0.26; RECTAS, P= 2.5 × 10−8; b-RECTAS 2 µM, 5.5 × 10−4; b-RECTAS 10 µM, 7.5 × 10−4; b-RECTAS
50 µM, 9.6 × 10−8) and one-tailed t test in (f) (vs. the 0 h control: 6 h, P= 1.6 × 10−2; 10 h, P= 2.8 × 10−5; 24 h, P= 4.8 × 10−2; wo, P= 0.18). No sample
was loaded in blank lanes in (c, d).
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Fig. 4 RECTAS restores IKBKAP-familial dysautonomia (FD) exon 20 inclusion in patient induced pluripotent stem cells-derived sensory neurons
(iPSC-SNs) and transgenic mice. a Diagram for preparation of iPSC-SNs, showing time-course (upper), microscopic images of spheroids at day 2 (lower,
left), and differentiated iPSC-SNs on day 5 (lower middle for brightfield and lower right for BRN3A/SOX10/Nucblue/TUBB3 immunocytostaining image).
BF, bright field image; scale bars, 100 µm. b, c RT-PCR for IKBKAP exon 19–21 and ACTB as a loading control for differentiated iPSC-SNs from a healthy
donor (WT) or FD patient (FD) on day 12 (b), and iPSC-SNs (day 12) treated with CaNDY (10 µM) or 0.1% DMSO for 2 h, followed by addition of RECTAS
(10 µM) or 0.1% DMSO in media and subsequent incubation for 22 h (c). IKBKAP and ACTB were detected with primers oAM138+ oAM139 and oAM13+
oAM14, respectively. d, e Microscopic images (d) and quantification for the extent of IKBKAP-FD exon 20 inclusion (e), following treatment with RECTAS
(10 µM for (d), and 2 and 10 µM for (e)) or solvent only (0.1% DMSO) for 24 h in neuro 2A cells transfected with the IKBKAP-FD reporter. Bars, 100 µm in
(d). f RT-PCR for exogenous human IKBKAP (oAM124+ oAM126, primers designed for vector backbone) and endogenous mouse Ikbkap (oAM666+
oAM667, primers designed for exon 18 and 20) in neuro 2A cells transfected with IKBKAP-WT or -FD reporter and treated with 2 or 10 µM RECTAS or
0.1% DMSO for 24 h. Actb (oAM364+ oAM366) served as a loading control. g Quantification of PSI for IKBKAP-FD exon 20 in DRG from IKBKAP-FD-
humanized transgenic mice administered RECTAS (300, or 400mg/kg BW, p.o.) with a booster administration of the same dose at 4 h, and DRG were
collected 8 h after the first administration to be applied for RT-PCR for IKBKAP exon 19–21 with primer set of HsIKAPRT18F+HsIKAPRT21R (n= 2 for no
treatment, n= 6 for MOCK, n= 5 for 300mg/kg BW RECTAS, and n= 3 for 400mg/kg BW RECTAS). MOCK, control for the vehicle only. h RT-PCR for
Rbm24 in blood cells, skeletal muscle, and liver tissues from 2-month-old B6 mouse, as well as DRG from MOCK or RECTAS (300mg/kg BW)-
administered IKBKAP-FD transgenic mice. Actb served as a loading control. Rbm24 and Actb were detected by primers Rbm24-F+ Rbm24-R and oAM365
+ oAM366, respectively. Data from three iPSC clones are shown in (a–c), four replicates were shown in (d–e), two replicates are shown in (f).
Representative data from two experiments are shown in (h). E20 (+), exon 20 inclusion product; E20 (−), exon 20 skipping product; E19 (+), exon 19
inclusion product; E19 (−), exon 19 skipping product in (b), (c), and (f). Columns, mean; bars, SE; n.s., P≥ 0.05; **P < 0.01; ***P < 0.001 for unpaired two-
tailed t test in (e) (vs. DMSO control: 2 µM, P= 5.6 × 10−5; 10 µM, P= 1.5 × 10−4) and (g) (vs. MOCK control: no treat, P= 0.97; 300mg/kg BW, 2.4 × 10
−3; 400mg/kg BW, 1.0 × 10−2); PSI, percent spliced-in in (b), (c), and (f); ND, not detectable in (f).
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we measured the effect of per os (p.o.) administration of
RECTAS, using previously established IKBKAP-FD transgenic
mice, in which an IVS20+ 6 T > C-mutant human IKBKAP gene
was introduced in a BAC clone, in the presence of the
endogenous murine wild-type Ikbkap, as an asymptomatic
splicing model42. RECTAS was orally administered at 300 or
400 mg/kg body weight (BW) with a booster administration at 4 h
intervals. Eight hours after the first administration, total RNA was
extracted from dorsal root ganglia (DRG) to assess the splicing
profile in sensory neurons. RT-PCR revealed enhanced inclusion
(about 70% increase in PSI from ~12.5 to ~22%) of IKBKAP-FD
exon 20 following RECTAS administration at both doses in DRG
(Fig. 4g). We subsequently conducted transcriptome analysis for
DRG, excised from MOCK and RECTAS-treated (300 mg/kg
BW) groups. We found IKBKAP-FD exon 20 inclusion among
the highly promoted exons (13th highest alterations) (Supple-
mentary Fig. 5 and Supplementary Data 2), consistent with its
selective effect in patient primary fibroblasts (Fig. 1b, c and
Supplementary Data 1). Moreover, we confirmed there was no
Rbm24 expression detectable in DRG irrespective of RECTAS
administration (Fig. 4h), ruling out the involvement of Rbm24 as
shown for human tissue cultures (Fig. 1d). Finally, we assessed
the preclinical profile of RECTAS, checking for effects on body
weight change and food consumption, as well as conducting
necropsy and hematology tests, both after single p.o. administra-
tion (0, 100, 300, 1000 mg/kg BW) and 14-day repetitive p.o.
administration (0, 40, 200, and 1000 mg/kg BW/day) (Supple-
mentary Table 1). There was no genotoxicity for RECTAS in the
micronucleus and Ames tests (Supplementary Table 1). These
preclinical data together indicate that there was no anticipated
adverse effect associated with RECTAS administration, assu-
mingly due to its high target selectivity for IKBKAP-FD exon 20
(Fig. 1b, c and Supplementary Fig. 5).
Discussion
Recent studies revealed that the prevalence of splicing mutations
is much higher than previously thought, as ~30–50% of disease-
associated mutations are estimated to cause abnormal
splicing43,44, and the total number is further increasing due to the
identification of deep-intronic splicing mutations through recent
whole-genome sequencing and transcriptome analysis13,45–48.
Therefore, an innovative therapeutic strategy to target mis-
regulation of splicing is urgently needed. Small-molecule com-
pounds that target trans-acting splice factors offer an opportunity
to systematically target a particular set of mis-splicing events that
are regulated by a similar splicing context. In this study, we
identified alternative exons that show a dependency on a subset of
SRSFs and CLK kinases are rational targets for selective manip-
ulation in both promotive and suppressive ways (Fig. 5). Our data
indicate that enhanced SRSF6 activity is a crucial aspect of the
splicing environment induced by RECTAS treatment, and the
requirement of CLKs in this process suggests that the direct
interaction of RECTAS with CLK1 (Fig. 3c, d) sterically activates
cellular CLK1. As a precedent for PDK1, the regulatory kinase of
AGC kinases, there is an allosteric small-molecule activator that
binds to the HM/PIF-pocket to induce a conformational
change49. We assume that RECTAS binding modifies the intra-
molecular conformation of CLK1 to promote its catalytic activity
or provide accessibility of a signal mediator upstream of CLK1.
Understanding the binding mode of RECTAS to CLK1 and the
activating pathway for CLKs in the context of suboptimal donor
RNA recognition by SRSF6 will provide further insights into this
regulation.
We found that RECTAS p.o. administration of 200–300 mg/kg
BW for 8 h achieved ~22% PSI for exon 20 in DRG of IKBKAP-
FD transgenic mice, versus ~12.5% baseline PSI in mock or
untreated controls (Fig. 4g). In the recent report from Morini
et al.50, as little as ~12.5% of IKBKAP exon 20 PSI (versus ~10%
baseline) by kinetin administration (200 mg/kg BW/day in the
diet for 6 months) was sufficient for the phenotypic rescue of
sensory loss. Though these data were obtained with different
transgenic mice and cannot be directly compared, we expect that
RECTAS should exhibit higher therapeutic efficacy in vivo than
kinetin, which already completed a phase 1 clinical trial in FD
patients (NCT02274051 in ClinicalTrials.gov). Kinetin has been
reported to have high target selectivity in FD patient fibroblasts,
and our study revealed a similar target-selective profile for
RECTAS. Other RECTAS-responsive exons, such as TATA-box
binding protein associated factor, RNA polymerase I subunit A
(TAF1A) exon 4 and par-3 family cell polarity regulator (PARD3)
exon 21 (Supplementary Data 1) had no apparent effect on cell
viability. Presumably, this is because alternative splicing occurs
physiologically for most genes, and the safety profile determined
in preclinical tests further confirmed that RECTAS is well-
tolerated in rodents. In addition, we confirmed the higher activity
of RECTAS than previously reported IKBKAP splice modifiers in
a reporter assay (Fig. 2k), which further highlights the efficient
activity of RECTAS for IKBKAP-FD exon 20 inclusion. These
observations together suggest that RECTAS may prove to be a
Fig. 5 Diagram for bidirectional control of IKBKAP-FD exon 20 by small molecules. a SRSF6 binding at the ISE is a major factor in the therapeutic splicing
environment induced by RECTAS treatment. The requirement of CLK1 for this process and the direct interaction between CLK1 and RECTAS implies a steric
effect for the activation of cellular CLK1. b For its dependence on CLK1 and SRSF6 for recognition, IKBKAP-FD exon 20 splicing can be controlled in a reverse
direction by CLK inhibitor treatment.
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potent agent for the treatment of FD, and ongoing medicinal
chemistry indicates further improvement in potency.
Searching in existing databases, there are numerous splicing
mutations that resemble the context of IKBKAP-FD exon 20. For
example, a splicing mutation in the potassium voltage-gated
channel subfamily Q member 1 (KCNQ1), which is responsible for
congenital long QT syndrome type I, has a similar splice enhancer
motif, and the impaired exon of KCNQ1 is also manipulated
bidirectionally in a similar manner as IKBKAP IVS20+ 6 T > C
(our unpublished observations). The opportunity for bidirectional
regulation by CLK inhibitors and agonists offers a strategic
approach for individual splicing contexts, as promoting recog-
nition of a target exon, on the one hand, provides a therapeutic
effect for splicing mutations like the IVS20+ 6 T > C mutation of
IKBKAP, whereas inhibition of a target exon, on the other hand,
offers a therapeutic opportunity for splice-site-creating splicing
mutations, as we previously demonstrated the therapeutic effects
of CLK inhibitors in EDA-ID with the IVS6+ 866 C > T muta-
tion of NEMO13 and cystic fibrosis with the c.3849+ 10 kb C > T
mutation of CFTR11. CLK-targeting strategies may also become
increasingly relevant, as recent whole-genome and transcriptome
analyses highlighted the widespread presence of deep-intronic
mutations that lead to the creation of cryptic pseudoexons13,45–48.
In addition, numerous splicing mutations have also been
identified in recent cancer genomics studies51,52, although their
individual contributions to malignancy remain largely unknown.
CLK inhibitors (e.g., T-02553 and SM0850254) and SRPK inhi-
bitors (e.g., SPHYNX55,56, SRPIN34035, and SRPKIN-157)
described by other groups and us were recently reported to have
anti-cancer activity in several cancer types. Moreover, small-
molecule compounds that target the essential splice factor SF3B,
such as spliceostatin A and E710758,59, have shown efficacy in
leukemia models harboring mutations in the same or different
trans-acting splice factors, namely SF3B1, SRSF2, or U2AF35,
which sensitize the cells to the inhibitors60–63, though inhibition
of SF3B also evokes global intron retention and cytotoxicity. In
this regard, targeting CLKs by RECTAS, with a target selectivity
sufficient for a favorable safety profile in preclinical tests, may
provide an alternative therapeutic strategy to target cancer cells
with vulnerable splicing machinery or CLK-dependent causal
splicing misregulation.
Overall, our current observations with IKBKAP-FD exon 20
not only highlight RECTAS as a potential therapeutic agent for
FD but also suggest the feasibility of chemical control of disease-
associated missplicing by manipulating the splicing environment
composed of SRSFs and CLKs in target cells. Facing the
increasing prevalence of splicing mutations associated with
human diseases, mechanism-oriented precision medicine for
missplicing, as exemplified by this study, may provide a new
framework for targeting such splicing diseases.
Methods
Cell lines. HeLa cells were obtained from the Japanese Collection of Research
Bioresources (JCRB) Cell Bank of the National Institutes of Biomedical Innovation,
Health and Nutrition (NIBIOHN) (JCRB9004) (Osaka, Japan) and cultured in
Dulbecco’s modified Eagle medium (DMEM) (Bibco of Thermo Fisher Scientific,
Waltham, MA, USA) supplemented with 10% fetal bovine serum, 100 U/mL
penicillin, and 100 µg/mL streptomycin. Neuro 2A cells were obtained from JCRB
Cell Bank of NIBIOHN (IFO50081), and cultured in DMEM (GIBCO of Thermo
Fisher Scientific, Waltham, MA, USA) supplemented with 1× GlutaMAXI (GIBCO
of Thermo Fisher Scientific), 10% fetal bovine serum, 100 U/mL penicillin, and 100
µg/mL streptomycin. Fibroblasts from 19- and 26-year-old male patients with FD
were provided by Coriell Institute (Camden, NJ, USA) (GM02342 (P1) and
GM00850 (P2), respectively) and cultured in DMEM supplemented with 15% fetal
bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin. Primary fibro-
blasts from healthy donors (36-year-old male (TIG-114, C1) and 40-year-old
female (TIG-108, C2)) were obtained from JCRB Cell Bank of NIBIOHN, and
cultured in DMEM supplemented with 10% fetal bovine serum, 100 U/mL peni-
cillin, and 100 µg/mL streptomycin. All cells were maintained in a cell incubator at
37 °C with 5% CO2. The tissue culture study was conducted under ethical approval
by the ethics committee of Kyoto University Graduate School and Faculty of
Medicine.
iPSCs. Control- and patient-derived iPSCs C1 and M1 were established
previously24,64. iPSCs were maintained on Matrigel (Corning, #354277) as colonies
in mTeSR1 medium (STEMCELL Technologies, #85850), according to the man-
ufacturer’s protocol. iPSC-SNs were prepared following a published protocol24 with
several modifications; the undifferentiated iPSCs were trypsinized to single cells
and re-aggregated on AggreWell 800 plates (STEMCELL Technologies, 34815) in
Primate embryonic stem cell medium (REPROCELL, RCHEMD001) with bFGF (5
ng/mL, WAKO, 062-06661) and Y-27632 (10 µM, 036-24023). On day 5, spheroids
were transferred to Matrigel-coated cell culture plates and differentiated further.
The medium was gradually changed to DMEM/F12 supplemented with
N2 supplement, nonessential amino acids, and Glutamax supplement in the pre-
sence of LDN-193189 0.1 µM and SB431542 10 µM (Repro-nLS, Cellagen Tech-
nology, K6570-500) for days 0–4 and CHIR99021 3 µM, DAPT 10 µM, and SU5402
10 µM (n3i, Cellagen Technology, K6571-500) for days 2–11. On day 12, the
medium was changed to a 1:1 mixture of the above N2 medium and Neurobasal
medium supplemented with B27 supplement, and with brain-derived neurotrophic
factor 10 ng/mL, glia-derived neurotrophic factor 10 ng/mL, and dbcAMP 1mM
for maturation. For immunocytochemistry, cells were fixed with 4% paraf-
ormaldehyde for 15 min, permeabilized with 0.1% Triton X-100 in D-PBS (−) for
15 min, and blocked with 3% bovine serum albumin (BSA) in D-PBS (−) for 1 h.
Then the cells were incubated with primary antibodies in 3% BSA in D-PBS (−) for
2 h, followed by visualization with appropriate secondary antibodies. The nuclei
were counterstained with Hoechst 33342 (Thermo Fisher Scientific). Experiments
using iPSCs were conducted under ethical approval by the ethics committee of
Kyoto University Graduate School and Faculty of Medicine.
Antibodies. The following antibodies were used for Western blotting: anti-U1-70k
mouse monoclonal antibody (9C4.1) (05-1588, Merk Millipore, Burlington, MA) at
1:500; anti-SmB/B′ mouse monoclonal antibody (Y12) (MA5-13449, Thermo
Fisher Scientific) at 1:500; anti-CLK1 rabbit polyclonal antibody (ARP52021_P050,
Aviva systems biology, San Diego, CA) at 1:500; anti-CLK2 rabbit polyclonal
antibody (ab65082, Abcam, Cambridge, UK) at 1:500; anti-CLK3 rabbit polyclonal
antibody (3256, Cell Signaling Technology, Danvers, MA) at 1:500; anti-CLK4
rabbit polyclonal antibody (ab104321, Abcam) at 1:500; anti-β-actin mouse
monoclonal antibody (Ac-15) (sc-69879, Santa Cruz Biotechnology, Dallas, TX) at
1:4000; anti-SR protein (1H4G7) mouse monoclonal antibody (33–9400, Thermo
Fisher Scientific) at 1:200 for phosphorylated SR proteins; anti-Lamin B1
(EPR8985) rabbit monoclonal antibody (ab133741, Abcam, Cambridge, UK) at
1:500. The following antibodies were used for immunocytostaining: anti-OCT4
rabbit monoclonal antibody (T.631.9) (MA5-14845, Thermo Fisher Scientific) at
1:400, anti-SSEA4 mouse monoclonal antibody (MC-813-70) (MA1-021, Thermo
Fisher Scientific) at 1:500, anti-SOX10 rabbit monoclonal antibody (EPR4007)
(ab155279, Abcam) at 1:250, anti-BRN3A mouse monoclonal antibody (5A3.2)
(MAB1585, Merck Millipore) 1:200, and anti-beta III tubulin (TUBB3) rabbit
monoclonal antibody (EP1569Y) (ab52623, Abcam) 1:500. Counterstaining was
done with NucBlue cell stain (Thermo Fisher Scientific).
Compounds. Kinetin was purchased from Nacalai Tesque (Tokyo, Japan).
(−)-epigallocatechin gallate (EGCG), daidzein, genistein, epoxomicin, and borte-
zomib were purchased from FUJIFILM Wako Pure Chemical (Osaka, Japan). δ-
tocotrienol was produced by LKT Laboratories, Inc. (St. Paul, MN). Phosphati-
dylserine was produced by Larodan Fine Chemicals AB (Solna, Sweden). Digoxin
was produced by Cayman Chemical (Ann Arbor, MI). Carfilzomib was purchased
from Cell Signaling Technology. b-RECTAS was synthesized in-house from
RECTAS. Compound stock solutions were prepared with DMSO, except for
phosphatidylserine, which was dissolved in chloroform:methanol solution (95:5 %
volume).
IKBKAP (IVS20+6T>C) humanized mice. The IKBKAP (IVS20+ 6 T > C)
transgenic mouse strain used in this study was obtained from Drs. Pickel and
Slaugenhaupt42. Mice were bred in the light/dark cycle of 12 h/12 h, 40–60%
humidity and 69–72 °F temperature. RECTAS in suspension with 0.5% carbox-
ymethyl cellulose was administered to more than 8-week-old mice p.o. at a dose of
300 or 400 mg/kg BW. Four hours later, an equivalent booster dose was given, and
after another 4 h, the mice were euthanized and RNA extraction from dorsal root
ganglia was performed. Extracted RNA was further analyzed by RT-PCR to
measure the PSI value for exon 20 inclusion of IKBKAP. An animal study using
IKBKAP (IVS20+ 6 T > C) mice was conducted under ethical approval by Cold
Spring Harbor Laboratories.
Reverse transcription-coupled polymerase chain reaction (RT-PCR). Total
RNA purification was conducted by direct-zol RNA miniprep (zymo research,
Irvine, CA) or RNeasy mini kit (Hilden, Germany) from a cell line or homogenized
tissue block of C57BL/6 mouse in TRIzol (Thermo Fisher Scientific). Blood total
RNA from C57BL/6 mouse was extracted by NucleoSpin RNA blood column
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(Macherey-Nagel, Dueren, Germany), followed by addition of TRIzol (Thermo
Fisher Scientific) and another round of purification by direct-zol RNA miniprep
(zymo research). Total RNAs from human liver (No. 636531), kidney (No.
636529), lung (No. 636524), heart (No. 636532), and skeletal muscle (No. 636534)
were purchased from Takara Bio (Shiga, Japan). For RT-PCR, total RNA was
applied for reverse transcription by PrimeStar Reverse Transcriptase (Takara Bio)
with random hexamers, and the resulting products were amplified with ExTaq
DNA polymerase (Takara Bio) with target-specific primer sets. Primers used for
RT-PCR are listed in Supplementary Table 2. Detection was conducted with
ChemiDoc MP Imaging System (Bio-Rad, Hercules, CA) and analyzed by Image
Lab software (6.0.1) (Bio-Rad).
RNAi. RNAi was conducted by lipofection of small interfering RNA (siRNA)
(Silencer Select siRNA, Ambion of Thermo Fisher Scientific) targeting human SRSF1
(siRNA ID, s12725), SRSF2 (siRNA ID, s12728), SRSF4 (siRNA ID, s12735), SRSF6
(siRNA ID, s12741), SRSF7 (siRNA ID, s12743), SRSF8 (siRNA ID, s21495), SRSF9
(siRNA ID, s16546), SRSF10 (siRNA ID, s57794), SRSF11 (siRNA ID, s17770),
SRSF12 (siRNA ID, s43932), CLK1 (siRNA ID, s3162), CLK2 (siRNA ID, s3165),
CLK3 (siRNA ID, s3169), CLK4 (siRNA ID, s32988), DYRK1A (siRNA ID, s4400),
DYRK1B (siRNA ID, s17490), DYRK2 (siRNA ID, s16027), and DYRK3 (siRNA ID,
s16026) and a non-specific control (si-NS) (siRNA ID, 4390843) as a negative control.
For simultaneous knockdown of CLK isoforms and DYRK isoforms, mixture of
siRNAs targeting CLK1, 2, 3, and 4 and DYRK1A, 1B, 2, and 3 were transfected,
respectively. siRNA transfection was conducted using Lipofectamine RNAiMAX
(Thermo Fisher Scientific) with a final concentration of each siRNAs in the culture
medium set to 100 nM. Knockdown effects at the protein level were confirmed for
siRNAs targeting SRSF6, CLK1, CLK2, CLK3, and CLK4 (Supplementary Fig. 6).
Dual-fluorescence reporter system for splicing evaluation. We previously
constructed the SPREADD reporter system for IKBKAP IVS20+ 6 T > C17, in
which the splicing extent of IKBKAP exon 20 was quantified by the ratio of green
fluorescent protein (GFP) and red fluorescent protein (RFP). For the reporter
assay, the IKBKAP IVS20+ 6 T > C splicing reporter vector was transfected into
HeLa cells (0.1 × 106 cells/well, seeded in a 12-well plate) with Lipofectamine 2000
transfection reagent (Thermo Fisher Scientific) and changed to fresh media at 4–5
h after transfection to be incubated with or without compounds for 24 h before
sample preparation or fixation with 4% paraformaldehyde in phosphate-buffered
saline (pH 7.4). Fixed cells were then scanned with a BZ-X710 fluorescence
microscope (Keyence, Osaka, Japan), and analyzed for fluorescence intensities with
a hybrid-cell count software of BZ-X analyzer (1.4.0.1) (Keyence). The resulting
GFP/RFP fluorescence ratio was then plotted to indicate the relative extent of
IKBKAP exon 20 inclusion.
RNA pull-down assay and Western blot. Lysate for HeLa cell or primary
fibroblasts lysate was prepared in lysis buffer (10 mM Tris-HCl; pH 7.4), 150 mM
NaCl, 1 mM ethylenediaminetetraacetic acid, 1% Triton X-100, 0.1% sodium
dodecyl sulfate, 0.25% sodium deoxycholate, and 10% glycerol with protease-
inhibitor (Nacalai Tesque) and phosphatase-inhibitor (Sigma Aldrich)), followed
by sonication, treatment with DNase I (Promega, Madison, WI) at 37 °C for 5 min,
and centrifugation (18,500×g at 4 °C for 15 min). The supernatant was used as a
soluble fraction for RNA pull-down assay and western blot. For western blot,
soluble fraction was dissolved in Laemmli buffer and separated in 5–20% Tris-
glycine polyacrylamide gel (FUJIFILM Wako Pure Chemical). Separated proteins
were then transferred to the PVDF membrane, and processed for blocking with 5%
skim milk in Tris-buffered saline and incubation with antibody. For RNA pull-
down assay, 5′-biotin, 3′-dTdT-attached RNAs (5′-UUGGACAAGUAA-
GUGCCAUUGUACU-3′ (oAM153) for the IKBKAP exon 20 donor region of
reference sequence, 5′-UUGGACAAGUAAGCGCCAUUGUACU-3′ (oAM154)
for the IKBKAP exon 20 donor region with IVS20+ 6 T > C mutation, 5′-
UUGUACUGUUUGCGACUAGUUAGCU-3′ (oAM155) for the site-a, 5′-
GUUAGCUUGUGAUUUAUGUGUGAAG-3′ (oAM156) for the site-b, 5′-
AAGACAAUAAGUAUUUUAUUACAAU-3′ (oAM209) for the site-c, and 5′-
GUUAGCUUGUGAUUUAUAUACAAAG-3′ (oAM167) for the site-b(mt)) were
incubated with HeLa cell lysate (for oAM155, oAM156, oAM209, and oAM167) or
HeLa nuclear extract (for oAM153 and oAM154) in presence of 1% DMSO or 10
μM RECTAS (CILBIOTECH, s.a., Mons, Belgium) for 16 h with rotation at 4 °C,
followed by washing with Tris-buffered saline three times and eluting with
Laemmli buffer. Eluted proteins were then analyzed by Western blotting. Detection
was conducted with ChemiDoc MP Imaging System (Bio-Rad) and analyzed with
Image J (1.52a)65.
Compound pull-down assay. b-RECTAS was synthesized as a RECTAS analog
with IKBKAP exon 20-targeting activity with covalent biotin labeling. The resulting
b-RECTAS was used for the compound pull-down assay with neutravidin beads.
Neutravidin beads were incubated with 0, 100, or 200 nM of biotin-conjugated
RECTAS for 2 h at 4 °C. Following washing with Tris-buffered saline (pH 7.4), the
biotin-RECTAS-bound beads were then incubated with HeLa cell lysate or GST-
CLK1 recombinant protein expressed in Sf9 insect cells (ProQinase, Freiburg,
Germany) for 16 h at 4 °C. For competition assays, 100 nmol RECTAS was
incubated during the protein binding step, followed by washing and eluting with
Laemmli buffer. Eluted samples were analyzed by western blotting.
Cell viability assay. For cell viability assay, HeLa cells were seeded in a 96-well
plate in triplicate and incubated with compounds for 72 h. Cell viability was
measured by WST-8 assay using Cell Counting Kit-8 (Dojindo, Kumamoto, Japan).
Absorbance at 450 nm was measured with ARVO X5 multimode plate reader
(Perkin Elmer, Waltham, MA).
RNA-Seq. Total RNA was extracted from FD patient fibroblasts or DRG from
IKBKAP (IVS20+ 6 T > C) transgenic mice, using TRIzol (Thermo Fisher Scien-
tific) with DNase treatment. For FD patient fibroblasts, total RNA (2.5 µg) was
poly-A purified with a Dynabeads mRNA DIRECT Micro Kit (Thermo Fisher
Scientific), and used for library preparation with an Ion Total RNA-seq Kit v2
(Thermo Fisher Scientific). Single-end sequencing was performed on an Ion Proton
System (Thermo Fisher Scientific). For DRG from IKBKAP (IVS20+ 6 T > C)
transgenic mice, total RNA (0.6–0.7 µg) was poly-A purified and the library was
prepared with TruSeq stranded mRNA library kit (Illumina, Inc. San Diego, CA).
RNA-Seq was then conducted with NovaSeq 6000 (Illumina, Inc.), and Real-Time
Analysis (RTA) 1.9 software (Illumina, Inc.) was applied for primary data pro-
cessing. Sequence reads were split into 60-base fragments from the 5′ end and
mapped to the human genome (GRCh38) with STAR (ver. 2.4.1d), using the
Ensemble annotation GRCh38.94 as reference. 66 Sequence reads with average
Phred quality scores lower than 17, and those from rRNA, tRNA, snRNA, snoRNA,
or repetitive elements in the Repbase database67 were eliminated. To calculate the
PSI values, we used all internal exons from representative variants for each gene
selected based on the nucleotide sequences of variants and coding sequences in
UniProt68. The PSI value of the exon (n) was calculated as the number of junction
reads of exon (n− 1) and (n) divided by the sum of junction reads of exon (n− 1)
and (n) and exon (n− 1) and (n+ 1). For analysis of FD patient fibroblasts, PSI
values obtained from patient fibroblasts P1 and P2 were averaged, and exons with
more than 15 reads per million junction read for the sum of their skipping forms
and inclusion forms in DMSO and/or RECTAS-treatment conditions were used for
the analysis. The Sashimi plots were generated using an Integrated Genomic
Viewer (ver. 2.8.0)69. The RNA-seq data were deposited at the National Bioscience
Database Center database for patient fibroblasts (accession: hum0180), and at the
Gene Expression Omnibus of the National Center for Biotechnology Information
for transgenic mice (accession: GSE161109).
Statistics. The student’s t test was used to determine the statistical difference
between the two groups, and P values <0.05 were considered statistically significant.
Regression analysis for determination of EC50 and CT50 was conducted by
GraphPad Prism 7.05. (GraphPad Software, San Diego, CA).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All relevant data are available from the authors. The original RNA-seq data were
deposited at the National Bioscience Database Center database with the accession ID
hum0180 for patient fibroblasts, and at the Gene Expression Omnibus of the National
Center for Biotechnology Information for transgenic mice with the accession ID
GSE161109. The Repbase database is available at https://www.girinst.org/repbase/.
GRCh38 human reference genome and Ensemble annotation GRCh38.94 are available
from the Ensembl database (https://ensembl.org). Source data are provided with
this paper.
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